CC
IART icon

Claybrook Capital’s Integra LifeSciences IART Stock Holding History

Claybrook Capital’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-196
Closed -$9K – 350
2018
Q4 		$9K Buy
+196
New +$10.8K ﹤0.01% 490

Other funds holding IART

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Claybrook Capital's IART Position: Q1 2019 in Review

Claybrook Capital sold out of Integra LifeSciences (IART) in Q1 2019, closing a stake of 196 shares — an estimated $9K sold.

Claybrook Capital first reported a position in IART in Q4 2018 and held it in 1 quarter. The position peaked at $9K in Q4 2018. 259 funds tracked by Wall St. Rank hold IART as of Q1 2019.

  • Claybrook Capital reported no remaining Integra LifeSciences position as of Q1 2019 after selling out during the quarter.
  • Claybrook Capital sold 196 Integra LifeSciences shares in Q1 2019, an estimated $9K.
  • Claybrook Capital first reported a position in Integra LifeSciences in Q4 2018 and held it in 1 quarter.
  • Claybrook Capital's Integra LifeSciences position peaked at $9K in Q4 2018.
  • 259 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2019.

Based on Claybrook Capital's 13F filing for Q1 2019, filed 15 May 2019.